DDInter1021 DDInter1082
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Lanreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurasidone
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Lonafarnib
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Copper oxodotreotide Cu-64
Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Lanreotide may lead to a major life threatening interaction when taken with Lonafarnib
Lanreotide may lead to a major life threatening interaction when taken with Copper oxodotreotide Cu-64